Transcripts Abliva AB

Equities

Delayed Nasdaq Stockholm Other stock markets 08:10:13 2024-06-26 EDT			5-day change	1st Jan Change
0.136 ^SEK	-2.30%		-9.33%	-44.60%

05-30	Abliva Concludes Dosing in Mid-stage Study of Mitochondrial Disease Drug	MT
05-30	Abliva AB Announces Completion of 24 Weeks of Dosing in Wave 1 of the Falcon Study of KL1333 in Primary Mitochondrial Disease	CI

Transcript : Abliva AB - Special Call	05-21
Transcript : Abliva AB - Special Call	22-06-01
Transcript : Abliva AB Presents at BioStock Life Science Summit 2020, Nov-17-2020 01:05 PM	20-11-17

No results for this search